Literature DB >> 21626035

Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment.

Grazia Devigili1, Nurcan Uçeyler, Marcus Beck, Karlheinz Reiners, Guido Stoll, Klaus V Toyka, Claudia Sommer.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with variable involvement of other systems. A pathogenetic role of immune-mediated mechanisms has been suggested. We retrospectively analyzed sural nerve pathology and the clinical course in 18 patients with ALS. These patients had undergone sural nerve biopsy because of clinical or neurophysiological signs indicating sensory involvement (ALS+). Eleven of the 18 ALS+ patients had inflammatory cell infiltrates (ALS(vasc)) resembling infiltrates seen in patients with vasculitic neuropathy. Data were compared with the 7 patients without vasculitic infiltrates (ALS(nonvasc)) and with those of 16 patients with isolated peripheral nerve vasculitis (NP(vasc)). Biopsy specimens were processed with standard histological stains and with immunohistochemistry for a panel of inflammatory markers, with the hypothesis that the composition of infiltrates should differ between ALS(vasc) and NP(vasc). Immunoreactive cells were quantified in a blinded manner. Unlike patients with NP(vasc), those with ALS(vasc) had only minor neurophysiological abnormalities in the sural nerve and, except for the infiltrates, almost normal nerve morphology on semithin sections. The difference in epineurial T cell count was significant between ALS(vasc) and ALS(nonvasc) (p = 0.031). Surprisingly, the cellular composition of epineurial infiltrates in sural nerve biopsies was indistinguishable between ALS(vasc) and NP(vasc) despite a significant difference in fiber pathology (p < 0.0001). Standard immunosuppressive treatment did not prevent clinical progression of the motor neuron disease in any of the patients with ALS(vasc). ALS(vasc) appears as a neuropathological subtype in ALS+ suggesting immune-mediated disease components but without response to standard immunosuppressive treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21626035     DOI: 10.1007/s00401-011-0837-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  4 in total

1.  Sural nerve pathology in ALS patients: a single-centre experience.

Authors:  Marco Luigetti; Amelia Conte; Alessandra Del Grande; Giulia Bisogni; Angela Romano; Mario Sabatelli
Journal:  Neurol Sci       Date:  2011-12-28       Impact factor: 3.307

2.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

3.  Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.

Authors:  Benjamin J Murdock; Tingting Zhou; Samy R Kashlan; Roderick J Little; Stephen A Goutman; Eva L Feldman
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

4.  Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Francesco Gentile; Federica Cerri; Francesca Gallia; Paola Podini; Giorgia Dina; Yuri Matteo Falzone; Raffaella Fazio; Christian Lunetta; Andrea Calvo; Giancarlo Logroscino; Giuseppe Lauria; Massimo Corbo; Sandro Iannaccone; Adriano Chiò; Alberto Lazzerini; Eduardo Nobile-Orazio; Massimo Filippi; Angelo Quattrini
Journal:  Brain       Date:  2022-03-29       Impact factor: 13.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.